Galectin Therapeutics Inc.GALTNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-8.82%
↓ 101% below average
Average (39q)
-4.39%
Historical baseline
Range
High:45.96%
Low:-84.52%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -8.82% |
| Q2 2025 | 21.91% |
| Q1 2025 | 19.52% |
| Q4 2024 | -6.66% |
| Q3 2024 | 9.30% |
| Q2 2024 | -7.68% |
| Q1 2024 | -14.92% |
| Q4 2023 | 4.13% |
| Q3 2023 | -14.42% |
| Q2 2023 | 20.93% |
| Q1 2023 | -8.40% |
| Q4 2022 | -23.69% |
| Q3 2022 | 10.57% |
| Q2 2022 | 3.21% |
| Q1 2022 | -37.54% |
| Q4 2021 | 15.25% |
| Q3 2021 | -0.84% |
| Q2 2021 | -33.31% |
| Q1 2021 | 19.28% |
| Q4 2020 | -32.12% |
| Q3 2020 | 2.80% |
| Q2 2020 | -71.93% |
| Q1 2020 | 30.78% |
| Q4 2019 | -84.52% |
| Q3 2019 | 7.14% |
| Q2 2019 | -26.23% |
| Q1 2019 | 22.13% |
| Q4 2018 | -10.83% |
| Q3 2018 | 28.33% |
| Q2 2018 | 9.82% |
| Q1 2018 | -78.76% |
| Q4 2017 | 45.96% |
| Q3 2017 | 2.22% |
| Q2 2017 | 8.69% |
| Q1 2017 | -7.54% |
| Q4 2016 | -1.44% |
| Q3 2016 | 17.99% |
| Q2 2016 | 18.84% |
| Q1 2016 | -45.58% |
| Q4 2015 | 20.66% |